Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage

References

• Robert Koch Institute. Gesundheitsberichterstattung des Bundes, Gesundheit in Deutschland Aktuell (GEDA): Daten Und Fakten: Ergebnisse Der Studie “Gesundheit in Deutschland Aktuell 2009” . Berlin; 2011.
   Google Scholar
• Young BA , Lin E , Korff M , et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care . 2008;14(1):15–23.18197741
   PubMed Web of Science ®Google Scholar
• Wilke T , Groth A , Fuchs A , et al. Real life treatment of diabetes mellitus type 2 patients: an analysis based on a large sample of 394,828 German patients. Diabetes Res Clin Pract . 2014;106(2):275–285. doi:10.1016/j.diabres.2014.08.002 25176225
   PubMed Web of Science ®Google Scholar
• Norgaard ML , Andersen SS , Schramm TK , et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction–a nationwide study. Diabetologia . 2010;53(8):1612–1619. doi:10.1007/s00125-010-1783-z 20454950
   PubMed Web of Science ®Google Scholar
• Liebl A , Neiss A , Spannheimer A , Reitberger U , Wagner T , Görtz A . Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Dtsch Med Wochenschr . 2001;126(20):585–589. doi:10.1055/s-2001-14102 11402924
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas . 7th ed. 2015 Available from: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html. Accessed 7 7, 2019.
   Google Scholar
• Chang H-Y , Weiner JP , Richards TM , Bleich SN , Segal JB . Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care . 2012;18(11):721–726.23198714
   PubMed Web of Science ®Google Scholar
• Wilke T , Ahrendt P , Schwartz D , Linder R , Ahrens S , Verheyen F . Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland. Dtsch Med Wochenschr . 2013;138(3):69–75. doi:10.1055/s-0032-1327394 23299340
   PubMed Web of Science ®Google Scholar
• Schipf S , Werner A , Tamayo T , et al. Regional differences in the prevalence of known Type 2 diabetes mellitus in 45–74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabetic Med . 2012;29(7):e88–e95. doi:10.1111/j.1464-5491.2012.03578.x 22248078
   PubMed Web of Science ®Google Scholar
• Guariguata L , Whiting DR , Hambleton I , Beagley J , Linnenkamp U , Shaw JE . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract . 2014;103(2):137–149. doi:10.1016/j.diabres.2013.11.002 24630390
   PubMed Web of Science ®Google Scholar
• Pfeiffer AFH , Klein HH . The treatment of type 2 diabetes. Dtsch Arztebl Int . 2014;111(5):69–81;quiz 82. doi:10.3238/arztebl.2014.0069
   Web of Science ®Google Scholar
• Wilke T , Mueller S , Groth A , et al. Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Cardiovasc Diabetol . 2015;14:14. doi:10.1186/s12933-015-0179-2 25645749
   PubMed Web of Science ®Google Scholar
• Bundesärztekammer KV . Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften In: Nationale VersorgungsLeitlinie: Therapie Des Typ-2-Diabetes , 1st Auflage ed. 2013 Available from: http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/NVL_Typ-2_Therapie-lang_Apr_2014.pdf. Accessed 7 7, 2019.
   Google Scholar
• International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract . 2014;104(1):1–52. doi:10.1016/j.diabres.2012.10.001 24508150
   PubMed Web of Science ®Google Scholar
• McCarthy M . American Diabetes Association issues new guidelines for type 1 diabetes. BMJ . 2014;348:g4119. doi:10.1136/bmj.g4119 24942516
   PubMed Web of Science ®Google Scholar
• WIdO/DIMDI. Amtlicher ATC-Index mit DDD-Angaben für Deutschland im Jahr 2019. 2019 Available from: https://www.dimdi.de/dynamic/.downloads/arzneimittel/atcddd/atc-ddd-amtlich-2019.pdf. Accessed 2 19, 2019.
   Google Scholar
• Charlson M , Szatrowski TP , Peterson J , Gold J . Validation of a combined comorbidity index. J Clin Epidemiol . 1994;47(11):1245–1251. doi:10.1016/0895-4356(94)90129-5 7722560
   PubMed Web of Science ®Google Scholar
• Sundararajan V , Henderson T , Perry C , Muggivan A , Quan H , Ghali WA . New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol . 2004;57(12):1288–1294. doi:10.1016/j.jclinepi.2004.03.012 15617955
   PubMed Web of Science ®Google Scholar
• Slabaugh SL , Bouchard JR , Li Y , Baltz JC , Meah YA , Moretz DC . Characteristics relating to adherence and persistence to basal insulin regimens among elderly insulin-naïve patients with Type 2 diabetes: pre-filled pens versus vials/syringes. Adv Ther . 2015;32(12):1206–1221. doi:10.1007/s12325-015-0266-5 26563324
   PubMed Web of Science ®Google Scholar
• Perez-Nieves M , Kabul S , Desai U , et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin . 2016;32(4):669–680. doi:10.1185/03007995.2015.1135789 26703951
   PubMed Web of Science ®Google Scholar
• Hadjiyianni I , Desai U , Suzuki S , et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation: a retrospective database study among people with Type 2 diabetes mellitus in Japan. Diabetes Ther . 2017;8(1):149–166. doi:10.1007/s13300-016-0215-6 27913984
   PubMed Web of Science ®Google Scholar
• Nishimura R , Kato H , Kisanuki K , et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open . 2019;9(3):e025806. doi:10.1136/bmjopen-2018-025806
   PubMed Web of Science ®Google Scholar
• Jermendy G , Kiss Z , Rokszin G , Abonyi-Tóth Z , Wittmann I , Kempler P . Persistence to treatment with novel antidiabetic drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in people with type 2 diabetes: a nationwide cohort study. Diabetes Ther . 2018;9(5):2133–2141. doi:10.1007/s13300-018-0483-4 30120754
   PubMed Web of Science ®Google Scholar
• Ryden L , Grant PJ , Anker SD , et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J . 2014;35(27):1824. doi:10.1093/eurheartj/ehu076
   Web of Science ®Google Scholar
• Holden SE , Jenkins-Jones S , Currie CJ . Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes: a retrospective cohort study. PLoS One . 2016;11(5):e0153594. doi:10.1371/journal.pone.0153594 27152598
   PubMed Web of Science ®Google Scholar
• King P , Peacock I , Donnelly R . The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol . 1999;48(5):643–648. doi:10.1046/j.1365-2125.1999.00092.x 10594464
   PubMed Web of Science ®Google Scholar
• Shichiri M , Kishikawa H , Ohkubo Y , Wake N . Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care . 2000;23(Suppl 2):B21–B29.10860187
   PubMed Web of Science ®Google Scholar
• Gerstein HC , Bosch J , Dagenais GR , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med . 2012;367(4):319–328. doi:10.1056/NEJMoa1203858 22686416
   PubMed Web of Science ®Google Scholar
• Ray KK , Kendall DM , Zhao Z , et al. A multinational observational study assessing insulin use: understanding the determinants associated with progression of therapy. Diabetes Obes Metab . 2018. doi:10.1111/dom.13622
   Web of Science ®Google Scholar